ERBB2 and triple-negative breast carcinoma: Instead, BluePrint® took ER, PR, and HER2 IHC status as its starting point to develop gene expression patterns specifically able to discriminate between IHC hormone receptor-positive (HR+)/HER2-negative, HER2-positive (HER2+) and triple-negative breast cancer (TNBC)29.